Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 9, 2026, 6:27 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2329–2352 of 2,912 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Control Capsules Clear all

Conditions: Crohn's Disease
Interventions: RHB-104, Placebo; Drug
Lead sponsor: RedHill Biopharma Limited; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 331 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2019
U.S. locations: 43
States / cities: Tucson, Arizona • Anaheim, California • La Mirada, California + 37 more

Conditions: Parkinson's Disease
Interventions: Inosine, Placebo; Drug
Lead sponsor: Michael Alan Schwarzschild; Other
Eligibility: 30 Years and older
Enrollment: 298 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 61
States / cities: Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 51 more

Conditions: Depressive Disorder, Major
Interventions: Desvenlafaxine Succinate Sustained-Release (DVS SR), Placebo, Duloxetine 60 mg/day; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 638 participants
Timeline: 2006 – 2007
U.S. locations: 22
States / cities: Beverly Hills, California • Burbank, California • Encino, California + 19 more

Conditions: Parkinson Disease
Interventions: BMS-9894923; Drug
Lead sponsor: Allyx Therapeutics; Industry
Eligibility: 50 Years to 80 Years
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Aging, Testosterone Deficiency
Interventions: AlphaFen fenugreek 400 mg, AlphaFen fenugreek 500 mg, Placebo; Dietary Supplement · Other
Lead sponsor: Jacksonville University; Other
Eligibility: 21 Years to 45 Years · Male only
Enrollment: 58 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017
U.S. locations: 1
States / cities: Jacksonville, Florida

Conditions: Total Knee Athroplasty
Interventions: Periarticular Injection (PAI), Saline Control Periarticular Injection (PAI); Drug
Lead sponsor: Hospital for Special Surgery, New York; Other
Eligibility: 25 Years to 80 Years
Enrollment: 94 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: New York, New York

Conditions: Recovery of Function (G11.427.698.620), Athletic Performance, Heart Rate Variability (HRV)
Interventions: Magnesium L-Threonate, Placebo; Dietary Supplement · Other
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 18 Years to 35 Years
Enrollment: 109 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: PFIC1, PFIC2
Interventions: A4250 (odevixibat), Placebo; Drug
Lead sponsor: Albireo; Industry
Eligibility: 6 Months to 18 Years
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 12
States / cities: Los Angeles, California • San Francisco, California • Denver, Colorado + 8 more

Conditions: Iron Deficiency (Without Anemia)
Interventions: Placebo, Ferrous sulfate; Dietary Supplement
Lead sponsor: Cornell University; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 68 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2000
U.S. locations: 1
States / cities: Ithaca, New York

Conditions: Diabetes
Interventions: Cyclo-Z, Placebo; Drug
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years and older
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 1
States / cities: West Los Angeles, California

Conditions: Major Depressive Disorder, Depression
Interventions: TC-5214 + citalopram, Placebo + citalopram; Drug
Lead sponsor: Targacept Inc.; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 574 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 3
States / cities: Miami, Florida • Cincinnati, Ohio • Dallas, Texas

Conditions: Treatment-resistant Schizophrenia
Interventions: Evenamide 15 mg bid, Placebo; Drug
Lead sponsor: Newron Pharmaceuticals SPA; Industry
Eligibility: 18 Years and older
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 5
States / cities: Los Angeles, California • Miami, Florida • Atlanta, Georgia + 2 more

Conditions: Cystic Fibrosis, Exocrine Pancreatic Insufficiency
Interventions: EUR-1008 (APT-1008), Placebo; Drug
Lead sponsor: Forest Laboratories; Industry
Eligibility: 7 Years and older
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006
U.S. locations: 1
States / cities: Tyler, Texas

Conditions: Hepatitis C Virus
Interventions: BMS-791325, Placebo; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 20 Years to 49 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Cypress, California

Conditions: Agitation Associated With Alzheimer's Disease Dementia
Interventions: EXV-802, Placebo, EXV-801; Drug
Lead sponsor: Exciva GmbH; Industry
Eligibility: 55 Years to 90 Years
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 8
States / cities: Murrieta, California • Indianapolis, Indiana • Flowood, Mississippi + 5 more

Conditions: Depression
Interventions: Duloxetine, Escitalopram, BMS-820836 Placebo, BMS-820836; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 976 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 48
States / cities: Birmingham, Alabama • Little Rock, Arkansas • Chino, California + 41 more

Conditions: Alzheimer's Disease
Interventions: T3D-959, Placebo Comparator; Drug · Other
Lead sponsor: T3D Therapeutics, Inc.; Industry
Eligibility: 50 Years to 90 Years
Enrollment: 376 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Influenza
Interventions: DAS181, Placebo; Drug
Lead sponsor: Ansun Biopharma, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: Miramar, Florida

Conditions: Pulmonary Disease, Chronic Obstructive
Interventions: tiotropium 18 mcg, tiotropium 1.25 mcg (2 actuations/day), tiotropium 2.5 mcg (2 actuations/day); Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 40 Years and older
Enrollment: 17,183 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 303
States / cities: Athens, Alabama • Birmingham, Alabama • Florence, Alabama + 243 more

Conditions: Older Adults, Bioelectrical Impedance, Appetite Hormones, Metabolic Health, Body Composition Measurement, Cognitive Health
Interventions: Synbiotic supplement; Dietary Supplement
Lead sponsor: Texas Tech University; Other
Eligibility: 65 Years and older
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Lubbock, Texas

Conditions: Covid19
Interventions: Disulfiram, Placebo; Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 2
States / cities: Fresno, California • San Francisco, California

Conditions: Fatty Liver Disease, Fibrosis, Liver, Cirrhosis, Liver, Steatohepatitis, Nonalcoholic
Interventions: Align Probiotic Supplement Capsule, Placebos; Drug
Lead sponsor: Corewell Health East; Other
Eligibility: 18 Years and older
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Farmington Hills, Michigan

Conditions: Melanoma
Interventions: Spartalizumab, Placebo, Dabrafenib, Trametinib; Biological · Other · Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 100 Years
Enrollment: 568 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2024
U.S. locations: 12
States / cities: Encinitas, California • Orange, California • San Francisco, California + 9 more

Conditions: Trigeminal Neuralgia
Interventions: Basimglurant, Placebo; Drug · Other
Lead sponsor: Noema Pharma AG; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 166 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 8
States / cities: La Jolla, California • Miami, Florida • Tampa, Florida + 5 more

Search by objective public record fields.

Efficacy and Safety of Anti-MAP Therapy in Adult Crohn's Disease

Study of Urate Elevation in Parkinson's Disease, Phase 3

Study Evaluating Desvenlafaxine Succinate Sustained Release (DVS SR) In The Treatment Of Major Depressive Disorder

A Study to Assess the Safety of BMS-984923 Compared to Placebo, in People With Parkinson's

The Efficacy of Fenugreek Supplementation on Men's Health

Does PAI Reduce Pain After TKA Among Knee Arthroplasty Patients Receiving ACB & IPACK?

Effects of Magnesium L-Threonate on Sleep, Recovery, and Athletic Performance in Collegiate Athletes

This Study Will Investigate the Efficacy and Safety of A4250 in Children With PFIC Types 1 or 2

Supplemental Iron Improves Submaximal Exercise Performance in Non-anemic Iron Depleted Women

Development of A Novel Anti-Hyperglycemic Agent

TC-5214 as add-on the Treatment of Major Depressive Disorder

Evenamide, a Glutamate Release Modulator, as Add-On to Standard of Care in Subjects With Documented Treatment-Resistant Schizophrenia

Study to Evaluate the Safety and Efficacy of EUR-1008 (APT-1008) Pancreatic Enzyme Product in Participants With Cystic Fibrosis and Exocrine Pancreatic Insufficiency

Japanese Bridging Study Conducted in the United States

Safety and Efficacy of EXV-802 and EXV-801 in the Treatment of Agitation in Alzheimer's Disease Dementia

Efficacy and Safety of Fixed Doses of BMS 820836 in the Treatment of Patients With Treatment Resistant Major Depression

A Phase 2b/3 Clinical Study Evaluating T3D-959 in Mild-to-Moderate Alzheimer's Disease Subjects

Single Dose Escalating Study of DAS181 in Adults

Comparison of Tiotropium in the HandiHaler Versus the Respimat in Chronic Obstructive Pulmonary Disease

Effects of a Synbiotic Supplement on Metabolic & Cognitive Outcomes Among Older Adults

DISulfiram for COvid-19 (DISCO) Trial

Effect of Probiotics in Non-alcoholic Fatty Liver Disease and Steatohepatitis

A Study of the Anti-PD1 Antibody PDR001, in Combination With Dabrafenib and Trametinib in Advanced Melanoma

An Efficacy and Safety Study of Basimglurant (NOE-101) in Patients With Trigeminal Neuralgia.